logo
Bolton's best and worst GPs as rated by patients

Bolton's best and worst GPs as rated by patients

Yahoo14 hours ago
The best and worst GP surgeries in the borough as rated by patients have been revealed.
A total of 96 per cent of patients at Halliwell Surgery 2, in Lindfield Drive, rated it either 'very good' or 'fairly good' in the 2025 GP Patient Survey, up from 77 per cent last year.
The practice finished above last year's top performing practice, Dr Zarrouk & Partners, also known as Bradford Street Surgery, which has moved down to fourth place with a still impressive 92 per cent of patients rating the surgery good.
Dr Awan Abbas, of Halliwell Surgery 2, said: "We are incredibly honoured to be voted the best GP surgery in Bolton.
Halliwell Surgery 2 on Lindfield Drive was voted the best by patients in this year's GP Patient Survey. (Image: Google Maps)
"This recognition is a reflection of the hard work, dedication, and compassion shown by every member of our team - from our reception staff and admin team to our nurses and doctors.
"We are deeply grateful to our patients for their trust and ongoing support.
"Our focus has always been to provide safe, high-quality, and patient-centred care, and this recognition inspires us to continue striving for excellence in all the services we provide to our patients."
Meanwhile, the 3D Medical Centre in Deane Road, finished in last position with 52 per cent of patients rating the practice as "good".
READ MORE:
A total of 2,721,415 questionnaires were sent out nationally, and 702,837 were returned completed between December 30 last year and April 1.
This represents a response rate of 25.8 per cent.
Across the country, 75.4 per cent said their overall experience of their GP practice was good, an increase from the previous year.
A total of 92.5 per cent said they had confidence and trust in the healthcare professional at their last appointment.
However, just over half of respondents said that it was easy to contact their GP practice over the phone at 52.9 per cent.
The GP Patient Survey was carried out by NHS England with Ipsos.
Patients were asked a range of questions about their experiences of their practices including accessing appointments and accessing online services or out-of-hours services.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Physician associates should ‘never be used to replace doctors'
Physician associates should ‘never be used to replace doctors'

Yahoo

timean hour ago

  • Yahoo

Physician associates should ‘never be used to replace doctors'

Patient safety will be at the forefront of changes to the roles of NHS physician associates (PAs), who should 'never be used to replace doctors', the Health Secretary has said. Wes Streeting pledged to implement in full the findings of a review which said PAs must not diagnose patients when they come into A&E or GP practices and must be renamed as 'physician assistants'. Mr Streeting ordered the review into PAs and anaesthesia associates (AAs) after concerns were raised over whether they were safe and the impact on the training of junior doctors. The review, chaired by Professor Gillian Leng, who is president of the Royal Society of Medicine, made 18 recommendations. Mr Streeting said: 'Patients should always know who they are being treated by and should always receive appropriate care. 'Legitimate concerns about patient safety have been ignored for too long – that's why I sought out the very best clinical advice to review physician associates and anaesthesia associates' roles in the NHS. 'We're accepting all of the recommendations of the Leng review, which will provide clarity for the public and make sure we've got the right staff, in the right place, doing the right thing. Patients can be confident that those who treat them are qualified to do so. 'Physician assistants, as they will now be known, will continue to play an important role in the NHS. They should assist doctors, but they should never be used to replace doctors.' Prof Leng's review suggested a major change to the role of PAs after it acknowledged they have been used as substitutes for doctors, despite having significantly less training. More than 3,500 PAs and 100 anaesthesia associates (AAs) are working in the NHS and there have been previous calls for an expansion in their number. But a general lack of support for both roles from the medical profession – plus high-profile deaths of patients who were misdiagnosed by PAs – led to the review. Presenting her findings, Prof Leng said: 'Crucially I'm recommending that PAs should not see undifferentiated or untriaged patients. 'If (patients) are triaged, they (PAs) should be able to see adult patients with minor ailments in line with relevant guidance from the Royal College of GPs.' She said more detail was needed on which patients can be seen by PAs and national clinical protocols will now be developed in this area. She added: 'Let's be clear, (the role of PAs) is working well in some places, but there indeed has been some substitution and any substitution is clearly risky and confusing for patients.' Newly qualified PAs will also now work in hospitals for two years before they are allowed to work in GP surgeries or mental health trusts. The study said safety concerns in relation to PAs were 'almost always about making a diagnosis and deciding the initial treatment, particularly in primary care or the emergency department, where patients first present with new symptoms'. It added: 'It is here that the risk of missing an unusual disease or condition is highest, and where the more extensive training of doctors across a breadth of specialties is important. 'Making the wrong initial diagnosis and putting patients on an inappropriate pathway can be catastrophic.' Despite the shorter two years of training for PAs, where local NHS services have struggled with filling roles, 'the easy option in some cases was simply to fill gaps in medical rotas with PAs', the report went on. When it comes to the safety of PAs and AAs, Prof Leng said the 'evidence is poor', with 'no compelling evidence' in published research 'that PAs were safe to work as doctor substitutes in primary care'. Prof Leng concluded there were 'no convincing reasons to abolish the roles of AA or PA' but there is also no case 'for continuing with the roles unchanged'. She recommended that both PAs and AAs should have the opportunity for ongoing training and development, with potential to prescribe medicines in the future, and they should also should have the opportunity to become an 'advanced' PA or AA. Six patient deaths linked to contact with PAs have been recorded by coroners in England. One high-profile death involved Emily Chesterton, 30, who died from a pulmonary embolism. She was misdiagnosed by a PA on two occasions and told she had anxiety. NHS England has written to NHS trusts setting out the new changes, saying PAs currently working in primary care, emergency departments or any other setting must not triage patients or see undifferentiated patients without a diagnosis.

Former Chief Software Architect and Technology Advisor of Ontario Ministry of Health Orchestrates Groundbreaking Transformation in AI-Driven Cancer Diagnostics and National Healthcare Equity
Former Chief Software Architect and Technology Advisor of Ontario Ministry of Health Orchestrates Groundbreaking Transformation in AI-Driven Cancer Diagnostics and National Healthcare Equity

Associated Press

timean hour ago

  • Associated Press

Former Chief Software Architect and Technology Advisor of Ontario Ministry of Health Orchestrates Groundbreaking Transformation in AI-Driven Cancer Diagnostics and National Healthcare Equity

We are not just building smarter systems; we are creating a future where every patient, no matter their background, has access to life-saving care. Artificial Intelligence is transforming cancer diagnostics in Canada, enabling earlier detection, improved accuracy, and equitable access to care. At the forefront of this shift is Hugo Raposo, former Chief Software Architect and Technology Advisor for the Ontario Ministry of Health, whose work integrates machine learning and precision medicine into healthcare systems to bridge gaps for underserved communities. These innovations are setting new standards for ethical and personalized care. Hugo Raposo, one of Canada's foremost technology visionaries and the former Chief Software Architect and Technology Advisor for the Ontario Ministry of Health, is leading a nationwide transformation that is redefining the future of cancer care through Artificial Intelligence (AI). With nearly three decades of distinguished expertise in digital health transformation, enterprise architecture, and AI strategy, Raposo is setting a new benchmark for innovation at the intersection of technology and public health. At a time when cancer rates are projected to increase by over 60% globally in the next two decades, Raposo's initiatives arrive as a beacon of innovation and hope. He has spearheaded the development of intelligent healthcare platforms that integrate advanced machine learning, deep neural networks, and precision medicine into the core of cancer diagnostics. These groundbreaking advancements are not only enabling earlier and more accurate detection of malignancies but are also systematically dismantling the structural inequities that have long limited access to life-saving care for millions of Canadians. Driving the Intelligent Future of Cancer Care Raposo's vision comes to life in advanced AI systems designed to process and interpret vast, intricate medical imaging datasets with remarkable precision—spanning MRIs, CT scans, mammograms, and PET scans—to identify subtle, early indicators of cancer that frequently evade conventional diagnostic workflows. Under his leadership, these AI-powered solutions have achieved diagnostic performance on par with, and often surpassing, the most experienced human radiologists. This paradigm shift is transforming the diagnostic landscape by reducing variability, accelerating time-to-treatment, and delivering equitable outcomes across diverse populations. 'Artificial Intelligence is no longer a theoretical concept; it is a strategic necessity for healthcare systems intent on delivering equitable, high-quality outcomes,' stated Raposo. 'By embedding AI within our national healthcare infrastructure, we are not only bridging geographic and socioeconomic divides but also creating a scalable model for precision cancer care that can transform lives and future-proof our healthcare systems.' A Vision for National Health Equity Under Raposo's direction, AI-enabled portable imaging devices and secure, cloud-connected diagnostic platforms are being deployed in rural and underserved communities. These cutting-edge tools empower general practitioners and community health workers to conduct sophisticated cancer screenings with unprecedented accuracy. This approach has been instrumental in reducing diagnostic delays and ensuring that no Canadian's health outcome is determined by where they live or their socioeconomic status. 'Equity is not a byproduct of innovation; it must be embedded into every layer of our technological and clinical strategy,' Raposo emphasized. 'We are building systems that serve all Canadians equally, ensuring ethical guardrails, inclusivity, and fairness are central to every deployment.' By integrating multidimensional datasets—including genomic profiles, environmental factors, and behavioral patterns—Raposo's initiatives are advancing personalized oncology at scale. Predictive AI models designed under his stewardship enable clinicians to tailor screening protocols and treatment regimens to individual patients, maximizing clinical efficacy while minimizing unnecessary interventions and driving cost-effectiveness across Canada's healthcare system. Global Thought Leadership on Ethical AI Beyond his technical achievements, Raposo has emerged as a global authority on the ethical deployment of AI in healthcare. Recognizing the critical importance of data privacy, algorithmic fairness, and system transparency, he has championed frameworks that ensure AI technologies benefit all populations equitably. His contributions have made him a sought-after advisor to policymakers, health ministers, and international organizations striving to adopt AI responsibly and sustainably. 'Trust is the bedrock of transformative healthcare,' said Raposo. 'Our systems are designed with uncompromising commitments to patient privacy, data security, and algorithmic explainability to maintain public confidence and achieve long-term societal impact.' Expanding AI's Role in Canada's Healthcare Renaissance Raposo's work extends to fostering collaboration between technologists, clinicians, and public health leaders to create AI ecosystems that are robust, transparent, and adaptable. By cultivating partnerships with both public and private stakeholders, he has accelerated the integration of AI-driven tools into primary care and oncology programs nationwide. These initiatives have established Canada as a model for other nations seeking to modernize their healthcare systems while remaining attentive to ethical and equitable implementation. As AI becomes increasingly central to healthcare delivery, Raposo emphasizes the need for continuous innovation and vigilance. He has advocated for the creation of inclusive data repositories to ensure that AI models are trained on diverse and representative datasets. This effort is crucial to preventing algorithmic bias and achieving diagnostic accuracy across all demographic groups. About Hugo Raposo Hugo Raposo is a globally recognized Technology Advisor, Enterprise Architect, and AI Strategist who has dedicated his career to transforming healthcare systems through innovation. As the former Chief Software Architect and Technology Advisor for the Ontario Ministry of Health, he conceptualized and led transformative initiatives that modernized critical public health platforms. Under his leadership, scalable AI-powered diagnostic solutions were developed to improve outcomes for millions of citizens. Today, Raposo continues to shape the future of global healthcare, driving equitable access and ethical AI integration to redefine cancer care for the 21st century. Media Contact Company Name: Knewin Dino Contact Person: Caroline Silva Email: Send Email Country: Brazil Website: Press Release Distributed by To view the original version on ABNewswire visit: Former Chief Software Architect and Technology Advisor of Ontario Ministry of Health Orchestrates Groundbreaking Transformation in AI-Driven Cancer Diagnostics and National Healthcare Equity

Fact or Fiction: Endometrial Cancer
Fact or Fiction: Endometrial Cancer

Medscape

timean hour ago

  • Medscape

Fact or Fiction: Endometrial Cancer

Recent research emphasizes the importance of recognizing subclinical and early-stage endometrial cancer and the risks associated with delayed diagnosis, particularly among patients with metabolic syndrome, obesity, or other chronic health conditions. Improvements in diagnostic techniques and treatment modalities allow for a patient-centered, personalized approach, focusing not only on tumor eradication but also on overall health, quality of life, and long-term well-being. Although hormonal imbalance, particularly excess estrogen without sufficient progesterone, contributes significantly to the development of endometrial cancer, numerous other factors play critical roles. Specifically, women with Lynch syndrome have the highest risk for endometrial cancer (40%-60% lifetime risk), and research has shown that obesity and insulin resistance also drive its pathogenesis. Lifestyle factors, such as alcohol consumption and tobacco use, and psychological factors can further influence pathogenesis and prognosis. Learn more about the etiology of endometrial cancer. Total hysterectomy with bilateral salpingo-oophorectomy is the standard surgery for endometrial cancer, except in candidates for fertility-sparing options. Decisions regarding the addition of chemotherapy, radiation, or both depend on factors such as tumor stage, histologic subtype, grade, lymphovascular invasion, and molecular classification (eg, POLE mutations, p53 status, or mismatch repair deficiency). This individualized approach ensures that patients with low-risk disease are not overtreated while those with high-risk or advanced disease receive more aggressive and effective multimodal therapy. Learn more about treatment of endometrial cancer. Although hysterectomy is a key component of treatment, especially when performed with bilateral salpingo-oophorectomy, endometrial cancer can still recur. Up to 20% of patients will experience recurrence after hysterectomy, with most cases occurring within 2-3 years. Further, relapses can be local or include distant extrauterine manifestations. Therefore, ongoing surveillance through regular follow-up appointments, and imaging when necessary, is part of comprehensive care in both American and European recommendations. Learn more about the workup for endometrial cancer. Approximately 90% of patients with endometrial cancer will present with abnormal vaginal bleeding, with most cases occurring post-menopause. This has led to a belief that endometrial cancer is highly treatable because most patients with abnormal bleeding causes seek care when the cancer is still in early stages. However, mortality due to uterine cancer, of which endometrial cancer is the largest subgroup, has increased 1.25 times in all age groups throughout the 2000s. After presentation, an endometrial sample, which is easily obtained through office endometrial biopsy, can confirm the diagnosis, and further testing is then done to guide the course of treatment. Learn more about management guidelines for endometrial cancer. When fertility-sparing therapies are used in correctly selected patients, there is no significant adverse impact on survival. Specifically, patients with stage 1 endometrial cancer treated with fertility-sparing progestin therapy had comparable 5-year survival rates to those treated with hysterectomy, but comparable survival outcomes were not seen in those with higher-stage disease. According to National Comprehensive Cancer Network guidelines, patients must meet all of these criteria to be candidates for fertility-sparing treatment: grade 1 histology, disease limited to endometrium, absence of suspicious metastases, no contraindications to therapy or pregnancy, and counseling that this is not the standard of care. Learn more about management approaches to endometrial cancer.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store